文献速递糖尿病肥胖与代谢综合征

司美格鲁肽、替尔泊肽与SGLT2i在2型糖尿病中酒精相关结局的比较

Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

该目标试验模拟研究基于TriNetX电子健康记录数据,纳入新启用司美格鲁肽、替尔泊肽或SGLT2i的2型糖尿病成人,比较酒精使用障碍(AUD)相关住院或急诊就诊风险。结果显示,司美格鲁肽和替尔泊肽相比SGLT2i的AUD相关结局发生率更低(HR分别为0.54和0.61),而两药之间无差异(HR 0.98)。

要点

  • 司美格鲁肽相比SGLT2i与AUD相关住院/急诊风险降低相关(HR 0.54)。
  • 替尔泊肽相比SGLT2i与AUD相关住院/急诊风险降低相关(HR 0.61)。
  • 司美格鲁肽与替尔泊肽之间AUD相关结局风险无差异(HR 0.98)。

核心结论

  • 在2型糖尿病成人中,司美格鲁肽和替尔泊肽相比SGLT2i与临床记录的AUD相关结局发生率更低相关,两种GLP-1RA之间无差异。

研究设计与样本

  • 目标试验模拟研究,使用TriNetX研究网络去标识电子健康记录数据(2022年6月至2025年1月)。
  • 纳入新启用司美格鲁肽、替尔泊肽或SGLT2i的2型糖尿病成人。
  • 主要结局为临床记录的AUD住院或急诊就诊,采用1:1倾向评分匹配的Cox比例风险模型估计HR和95%CI。

主要发现

  • 平均随访0.81–1.02年,司美格鲁肽 vs SGLT2i的AUD住院/急诊发生率分别为2.42 vs 4.53/1000人年,HR 0.54(95%CI 0.45–0.64)。
  • 替尔泊肽 vs SGLT2i的发生率分别为2.34 vs 3.98/1000人年,HR 0.61(95%CI 0.46–0.83)。
  • 司美格鲁肽 vs 替尔泊肽的发生率分别为2.43 vs 2.36/1000人年,HR 0.98(95%CI 0.73–1.31),无差异。
  • 敏感性和亚组分析及次要结局结果一致。

临床怎么用

  • 对于2型糖尿病合并酒精使用障碍风险的患者,选择司美格鲁肽或替尔泊肽可能比SGLT2i更有利于降低AUD相关住院/急诊风险。
  • 司美格鲁肽与替尔泊肽在AUD相关结局方面效果相当,选择时可综合考虑其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To compare the risk of incident alcohol use disorder (AUD) among adults with Type 2 diabetes (T2D) initiating semaglutide, tirzepatide or sodium-glucose cotransporter-2 inhibitors (SGLT2i). Materials and Methods We conducted a target trial emulation using de-identified electronic health record data from the TriNetX research network (June 2022–January 2025). Adults with T2D newly initiating semaglutide, tirzepatide or an SGLT2i were included. The primary outcome was clinically recorded hospitalization or emergency department (ED) visits for AUD. Cox proportional hazards models with 1:1 propensity score matching (PSM) estimated hazard ratios (HRs) and 95% CIs. Sensitivity and subgroup analyses as well as secondary outcomes assessed the robustness of the findings. Results During a mean follow-up of 0.81–1.02 years, the incidence rates (IRs) of clinically recorded hospitalization or ED visits for AUD were 2.42 versus 4.53 per 1000 person-years for semaglutide versus SGLT2i, with an HR of 0.54 (95% CI, 0.45–0.64). Similarly, the IRs were 2.34 versus 3.98 per 1000 person-years for tirzepatide versus SGLT2i, with an HR of 0.61 (95% CI, 0.46–0.83). In the direct comparison of semaglutide versus tirzepatide, IRs were 2.43 and 2.36 per 1000 person-years, respectively, with no difference in risk (HR, 0.98; 95% CI, 0.73–1.31). Results were consistent across sensitivity and subgroup analyses and secondary outcomes. Conclusions In adults with T2D, semaglutide and tirzepatide were associated with lower rates of clinically recorded AUD-related outcomes than SGLT2i, with no difference between the two GLP-1RA medications.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。